October 2018

MDM2 Inhibitor May Improve Response in Acute Myeloid Leukemia

October 20, 2018

Clinical Trials in Progress

Investigators are hopeful that idasanutlin, a novel small molecule that targets the MDM2 protein, is being tested in combination with cytarabine in the international phase III MIRROS clinical trial (NCT02545283) to see if omprove the efficacy of chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML).

Bypassing the SICU May Improve Patient Outcomes

October 19, 2018

Partner Perspectives

Smilow Cancer Hospital tested sending patients directly from the post–anesthesia care unit (PACU) to the surgical oncology unit after head and neck surgery to reduce length of stay, postoperative complications, and readmission rates of patients.

Investigating the Potency of CAR T-Cell Therapy in Relapsed/Refractory MCL

October 19, 2018

Clinical Trials in Progress

The value of axicabtagene ciloleucel (axi-cel; Yescarta), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in treating R/R MCL will be tested in the multi­center phase II ZUMA-2 clinical trial (NCT02601313).